Evidence‑led, patient‑centered focal therapy

Our research (See our Literature) highlights what patients and providers value most: durable cancer control and preservation of urinary and sexual function. Multi‑hundred‑patient focal therapy series show early and sustained improvements in urinary satisfaction with modest sexual impact, complementing the five‑year oncologic durability seen in appropriately selected cohorts. We recommend featuring a concise literature hub by modality, alongside your practice’s outcomes dashboard as data matures.

Data Graphic

• ~86% cancer‑free at 5 years
• ~94–95% urinary function preserved
• ~88% erectile function maintained

Voices from the field

Short landing area for testimonials describe how sites integrated FOCALYX, how the first cases felt, and how surveillance runs in real life. Pair those with brief written quotes to help colleagues visualize the workflow and results.

Make it easy to take action

Invite teams to book a 20‑minute demo, request onboarding dates, or connect with an integration specialist. Reiterate that there’s no capital purchase required to get started, and that support—clinical, technical, and billing—is available at every step.

Compliance note: Clinical outcomes and payer coverage vary by patient, indication, provider experience, and contracts. Refer to current Instructions for Use and payer policies. Your team should review all statistics and claims against the latest internal data and published literature prior to publication.‍